Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Source :: GlobeNewswire. January 9, 2023
Publication Year :: 2023
Abstract: Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson's disease Further validation and expansion of Transport Vehicle (TV) technology, including multiple interim [...]

Subjects :: Sanofi S.A. -- Forecasts and trends
Medical research -- Forecasts and trends -- Health aspects
Medicine, Experimental -- Forecasts and trends -- Health aspects
Nervous system diseases -- Forecasts and trends -- Health aspects
Pharmaceutical industry -- Forecasts and trends
Market trend/market analysis
Banking, finance and accounting industries
Business

Tools